16588-69-5 Usage
Description
4-CHLORO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE, also known as 4-Chloro-1-isocyanato-2-(trifluoromethyl)benzene, is a clear colorless liquid with unique chemical properties. It is a compound that plays a significant role in the synthesis of various pharmaceuticals and has potential applications in the treatment of specific diseases.
Uses
Used in Pharmaceutical Synthesis:
4-CHLORO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE is used as a reagent for the synthesis of benzothiazole compounds, which target chemokine receptor 2. These compounds have potential applications in the treatment of anti-inflammatory diseases, making this isocyanate a valuable component in the development of new therapeutic agents.
Used in Anti-inflammatory Applications:
In the pharmaceutical industry, 4-CHLORO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE is used as a key intermediate in the development of drugs that target chemokine receptor 2. By modulating this receptor, the synthesized benzothiazole compounds can potentially alleviate the symptoms of various inflammatory diseases, offering a new avenue for treatment options.
Used in Chemical Research:
As a versatile chemical compound, 4-CHLORO-2-(TRIFLUOROMETHYL)PHENYL ISOCYANATE is also utilized in chemical research for the exploration of new reactions and the development of novel synthetic pathways. Its unique properties make it a valuable tool for scientists working in the fields of organic chemistry and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 16588-69-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,5,8 and 8 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 16588-69:
(7*1)+(6*6)+(5*5)+(4*8)+(3*8)+(2*6)+(1*9)=145
145 % 10 = 5
So 16588-69-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H3ClF3NO/c9-5-1-2-7(13-4-14)6(3-5)8(10,11)12/h1-3H
16588-69-5Relevant articles and documents
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer
Akwii, Racheal,Alvina, Karina,Ashraf-Uz-Zaman, Md,Farshbaf, Mohammad Jodeiri,German, Nadezhda A.,Kallem, Raja Reddy,Mikelis, Constantinos M.,Putnam, William,Sajib, Md Sanaullah,Shahi, Sadisna,Trippier, Paul C.,Wang, Wei,Zhang, Ruiwen
, (2020/10/12)
Triple-negative breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approximately one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel urea-based compounds with cytotoxicity against selected cell lines and with the ability to cross the blood-brain barrier in vivo. We have synthesized and analyzed a library of more than 40 compounds to elucidate the key features responsible for the observed activity. We have also identified FGFR1 as a molecular target that is affected by the presence of these compounds, confirming our data using in silico model. Overall, we envision that these compounds can be further developed for the potential treatment of metastatic breast cancer.
Synthesis of sulfilimines
-
, (2008/06/13)
Processes are disclosed for preparation of N-aryl-S,S-dihydrocarbylsulfilimines by reaction of phenylisocyanate compounds with hydrocarbyl sulfoxides. The sulfilimines can be rearranged to ortho-thioalkylene anilines and the reactions can be employed in a route for converting nitrobenzene compounds to ortho-thioalkylene anilines, which are useful intermediates for preparation of herbicidal compounds.
